Search

Displaying results 1801 - 1810 of 4591 in total
  1. Drug

    Ciforadenant

    go.drugbank.com/drugs/DB16125
    Investigational

    Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).

  2. Drug

    Calcium lactate

    go.drugbank.com/drugs/DB13231
    ApprovedVet approved

    It is prepared commercially by the neutralization of lactic acid with calcium carbonate or calcium hydroxide. … Approved by the FDA as a direct food substance affirmed as generally recognized as safe, calcium lactate is used as a firming agent, flavoring agent, leavening agent, stabilizer, and thickener [L2741].

  3. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Tofacitinib is marketed under the brand name Xeljanz by Pfizer. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.

  4. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    [A263376] Approved by the FDA in 1996,[A263366] irinotecan is used to treat colorectal cancer and pancreatic adenocarcinoma. … Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase I and blocking its enzymatic activity, thereby interfering with DNA synthesis.

  5. Drug

    Naloxone

    go.drugbank.com/drugs/DB01183
    ApprovedInvestigationalVet approved

    Also known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion. … [L33729,L33739] Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained

  6. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  7. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, ...

  8. Drug

    Diflunisal

    go.drugbank.com/drugs/DB00861
    Approved

    Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though it...

  9. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.

  10. Drug

    Izencitinib

    go.drugbank.com/drugs/DB16660
    Investigational

    Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).